$CTMX News

CytomX Therapeutics: Cashed Up With Catalysts Ahead

HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

CytomX (CTMX) Q1 2026 Earnings Transcript

CytomX Therapeutics Q1 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) Q1 2026 Revenue Beat Sparks Cautious Market Rally

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress

Analysts Bullish on CytomX Therapeutics (CTMX) As CTMX Prices $250 Million Offering

How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data

CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment

CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress

How The CytomX Therapeutics (CTMX) Narrative Is Shifting With New Colorectal Cancer Data

Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results

Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16